FAS and cancer: These findings suggest that elimination of CD95 or disruption of its homodimer complex in certain cancer cells might represent an attractive therapeutic option to prevent a CD95-dependent tumor growth and/or stimulate an inflammatory signal involved in the anti-tumor response of NK cells [66].